← Back to patent-cliff list
Sodium Pyruvate
Tier C — Watch / tradeSodium Pyruvate
Emphycorp Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Reactive oxygen species
Indications (approved)：Idiopathic pulmonary fibrosis, 新冠后遗症, COVID-19, Chronic obstructive pulmonary disease, Prostate cancer, Asthma, Cystic fibrosis, 脑癌
Regional status
US
Phase III
2021-04-12
EU
-
China
Phase II
2022-04-12
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sodium Pyruvate?
Approved indications include: Idiopathic pulmonary fibrosis, 新冠后遗症, COVID-19, Chronic obstructive pulmonary disease, Prostate cancer, Asthma, Cystic fibrosis, 脑癌.
When does the Sodium Pyruvate patent expire?
No public expiry year is available for Sodium Pyruvate yet; this page updates once verified.
How do I get a quote for Sodium Pyruvate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06